Medical marijuana for cancer

CA Cancer Journal for Clinicians

Volumn 65, Issue 2, 2015, Pages 110-122

  Kramer, Joan L ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

cannabidiol; cannabis; marijuana; tetrahydrocannabinol

Indexed keywords

ALIZAPRIDE; CANNABIDIOL; CANNABINOID; CANNABIS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOMPERIDONE; DOXORUBICIN; DRONABINOL; HALOPERIDOL; MEDICAL CANNABIS; MEGESTROL ACETATE; METHOTREXATE; METOCLOPRAMIDE; NABILONE; NABIXIMOLS; ONDANSETRON; PLACEBO; PROCHLORPERAZINE; ANALGESIC AGENT; ANTIEMETIC AGENT; DRUG COMBINATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVERSE DRUG REACTION; ANOREXIA; APPETITE; BILE DUCT CARCINOMA; BREAST CANCER; CANADA; CANCER PAIN; CANCER THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG INDICATION; DRUG MEGADOSE; DRUG USE; FOOD AND DRUG ADMINISTRATION; GLIOMA; HALLUCINATION; HUMAN; HYPOTENSION; LENNOX GASTAUT SYNDROME; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MULTIPLE SCLEROSIS; NAUSEA; NAUSEA AND VOMITING; PAIN; POSITIONAL DIZZINESS; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INDUCED EMESIS; REVIEW; SCHIZOPHRENIA; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SPASTICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; UNITED KINGDOM; UNITED STATES; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG COMBINATION; EVIDENCE BASED MEDICINE; NEOPLASMS; TREATMENT OUTCOME;

ANALGESICS, NON-NARCOTIC; ANTIEMETICS; CANADA; CANNABIDIOL; CLINICAL TRIALS AS TOPIC; DRONABINOL; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HUMANS; MEDICAL MARIJUANA; MULTIPLE SCLEROSIS; NEOPLASMS; PAIN; TREATMENT OUTCOME; UNITED STATES;

EID: 84924267939     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21260     Document Type: Review

References (151)

1. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD,. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009; 5: 153-168.
2. Clarke RC, Watson DP,. Cannabis and natural cannabis medicines. In, Elsohly M, ed. Marijuana and the Cannabinoids. Totowa, NJ: Human Press; 2007: 1-16.
3. Controlled Substances Act, 21 USC Chapter 13 (1970).
4. Moir D, Rickert WS, Levasseur G, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol. 2008; 21: 494-502.
5. Busch FW, Seid DA, Wei ET,. Mutagenic activity of marihuana smoke condensates. Cancer Lett. 1979; 6: 319-324.
6. Wu TC, Tashkin DP, Djahed B, Rose JE,. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med. 1988; 318: 347-351.
7. Grotenhermen F,. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003; 42: 327-360.
8. Gieringer D, St. Laurent J, Goodrich S,. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther. 2004; 4: 7-27.
9. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL,. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 2007; 82: 572-578.
10. Brenneisen R,. Chemistry and analysis of phytocannabinoids and other cannabis constituents. In:, Elsohly M, ed. Marijuana and the Cannabinoids. Totowa, NJ: Human Press; 2007: 17-51.
11. Pertwee RG,. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008; 153: 199-215.
12. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010; 35: 764-774.
13. Burgdorf JR, Kilmer B, Pacula RL,. Heterogeneity in the composition of marijuana seized in California. Drug Alcohol Depend. 2011; 117: 59-61.
14. French M,. Moms' Marijuana-for-Kids Campaign Seeks to Quiet Epilepsy. bloomberg.com/news/2014-07-28/moms-marijuana-for-kids-campaign-seeks-to-quiet-epilepsy.html. Accessed August 14, 2014.
15. Young S,. Marijuana Stops Child's Severe Seizures. cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/. Accessed August 14, 2014.
16. Gloss D, Vickrey B,. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014; 3: CD009270.
17. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK,. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980; 28: 409-416.
18. Guy GW, Flint ME,. A single centre, placebo-controlled, four period, crossover, tolerability study assessing pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based medicine extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT). J Cannabis Ther. 2003 (3/4): 35-77.
19. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA,. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011; 57: 66-75.
20. Stott CG, White L, Wright S, Wilbraham D, Guy GW,. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013; 69: 825-834.
21. Mechoulam R, Parker LA, Gallily R,. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002; 42 (suppl 11): 11S-19S.
22. AbbVie Inc. Marinol [package insert]. North Chicago, IL: AbbVie Inc; 2013. rxabbvie.com/pdf/marinol-PI.pdf. Accessed May 14, 2014.
23. Meda Pharmaceuticals Inc. Cesamet [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc; 2011. cesamet.com/pdf/Cesamet-PI-50-count.pdf. Accessed May 14, 2014.
24. ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults [ Clinicaltrials.gov identifier NCT02224560]. clinicaltrials.gov/show/NCT02224560. Accessed October 14, 2014.
25. ClinicalTrials.gov. A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome [ Clinicaltrials.gov identifier NCT 02091206]. clinicaltrials.gov/ct2/show/NCT02091206. Accessed October 14, 2014.
26. Clinicaltrials.gov. A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder [ Clinicaltrials.gov identifier NCT02006628]. clinicaltrials.gov/show/NCT02006628. Accessed October 14, 2014.
27. Chang AE, Shiling DJ, Stillman RC, et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med. 1979; 91: 819-824.
28. Chang AE, Shiling DJ, Stillman RC, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer. 1981; 47: 1746-1751.
29. Musty RE, Rossi R,. Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. J Cannabis Ther. 2001; 1: 29-56.
30. Sallan SE, Zinberg NE, Frei E, 3rd. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975; 293: 795-797.
31. Frytak S, Moertel CG, O'Fallon JR, et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med. 1979; 91: 825-830.
32. Kluin-Neleman JC, Neleman FA, Meuwissen OJ, Maes RA,. Delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. Vet Hum Toxicol. 1979; 21: 338-340.
33. Orr LE, McKernan JF, Bloome B,. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med. 1980; 140: 1431-1433.
34. Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P,. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust. 1979; 2: 657-659.
35. Sallan SE, Cronin C, Zelen M, Zinberg NE,. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1980; 302: 135-138.
36. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K,. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982; 50: 636-645.
37. McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS,. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs. 1988; 6: 243-246.
38. Lane M, Smith FE, Sullivan RA, Plasse TF,. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol. 1990; 13: 480-484.
39. Neidhart JA, Gagen MM, Wilson HE, Young DC,. Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol. 1981; 21 (suppl 8-9): 38S-42S.
40. Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG,. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J. 1980; 91: 449-451.
41. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007; 23: 533-543.
42. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991; 6: 352-359.
43. Ungerleider JT, Andrysiak TA, Fairbanks LA, Tesler AS, Parker RG,. Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy. Radiology. 1984; 150: 598-599.
44. Duran M, Perez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010; 70: 656-663.
45. Jones SE, Durant JR, Greco FA, Robertone A,. A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev. 1982; 9 (suppl B): 45-48.
46. Levitt M,. Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev. 1982; 9 (suppl B): 49-53.
47. Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE,. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev. 1982; 9 (suppl B): 39-44.
48. Crawford SM, Buckman R,. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother. 1986; 3: 39-42.
49. Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979; 300: 1295-1297.
50. Steele N, Gralla RJ, Braun DW Jr, Young CW,. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep. 1980; 64: 219-224.
51. Einhorn LH, Nagy C, Furnas B, Williams SD,. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol. 1981; 21 (suppl 8-9): 64S-69S.
52. Johansson R, Kilkku P, Groenroos M,. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev. 1982; 9 (suppl B): 25-33.
53. Ahmedzai S, Carlyle DL, Calder IT, Moran F,. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer. 1983; 48: 657-663.
54. Chan HS, Correia JA, MacLeod SM,. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics. 1987; 79: 946-952.
55. Niiranen A, Mattson K,. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol. 1985; 8: 336-340.
56. Dalzell AM, Bartlett H, Lilleyman JS,. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child. 1986; 61: 502-505.
57. Pomeroy M, Fennelly JJ, Towers M,. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol. 1986; 17: 285-288.
58. Niederle N, Schutte J, Schmidt CG,. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr. 1986; 64: 362-365.
59. Niiranen A, Mattson K,. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol. 1987; 10: 325-329.
60. Cunningham D, Forrest GJ, Soukop M, Gilchrist NL, Calder IT, McArdle CS,. Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs. Br Med J (Clin Res Ed). 1985; 291: 864-865.
61. Cunningham D, Bradley CJ, Forrest GJ, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol. 1988; 24: 685-689.
62. Priestman SG, Priestman TJ, Canney PA,. A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea. Clin Radiol. 1987; 38: 543-544.
63. Lewis IH, Campbell DN, Barrowcliffe MP,. Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. Br J Anaesth. 1994; 73: 244-246.
64. Milstein SL, MacCannell K, Karr G, Clark S,. Marijuana-produced changes in pain tolerance. Experienced and non-experienced subjects. Int Pharmacopsychiatry. 1975; 10: 177-182.
65. Cooper ZD, Comer SD, Haney M,. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology. 2013; 38: 1984-1992.
66. Greenwald MK, Stitzer ML,. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend. 2000; 59: 261-275.
67. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007; 107: 785-796.
68. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010; 182: E694-E701.
69. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009; 34: 672-680.
70. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007; 68: 515-521.
71. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H,. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013; 14: 136-148.
72. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL,. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011; 90: 844-851.
73. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT,. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010; 39: 167-179.
74. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT,. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013; 46: 207-218.
75. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012; 13: 438-449.
76. Lynch ME, Cesar-Rittenberg P, Hohmann AG,. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014; 47: 166-173.
77. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013; 260: 984-997.
78. Rog DJ, Nurmikko TJ, Friede T, Young CA,. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005; 65: 812-819.
79. Rog DJ, Nurmikko TJ, Young CA,. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007; 29: 2068-2079.
80. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S,. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010; 33: 128-130.
81. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D,. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007; 133: 210-220.
82. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS,. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006; 45: 50-52.
83. Haroutiunian S, Rosen G, Shouval R, Davidson E,. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. J Pain Palliat Care Pharmacother. 2008; 22: 213-217.
84. Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008; 9: 254-264.
85. Noyes R Jr, Brunk SF, Avery DA, Canter AC,. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975; 18: 84-89.
86. Noyes R Jr, Brunk SF, Baram DA, Canter A,. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975; 15: 139-143.
87. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ,. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003; 106: 169-172.
88. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D,. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain. 2004; 8: 173-177.
89. Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel BM,. Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil. 2010; 89: 840-848.
90. Svendsen KB, Jensen TS, Bach FW,. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004; 329: 253.
91. Maurer M, Henn V, Dittrich A, Hofmann A,. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci. 1990; 240: 1-4.
92. Raft D, Gregg J, Ghia J, Harris L,. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther. 1977; 21: 26-33.
93. Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012; 153: 2073-2082.
94. Bestard JA, Toth CC,. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 2011; 11: 353-368.
95. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D,. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 2008; 336: 199-201.
96. Pini LA, Guerzoni S, Cainazzo MM, et al. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain. 2012; 13: 677-684.
97. Skrabek RQ, Galimova L, Ethans K, Perry D,. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008; 9: 164-173.
98. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol. 2006; 253: 1337-1341.
99. Pooyania S, Ethans K, Szturm T, Casey A, Perry D,. A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil. 2010; 91: 703-707.
100. Beaulieu P,. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006; 53: 769-775.
101. Kalliomaki J, Philipp A, Baxendale J, Annas P, Karlsten R, Segerdahl M,. Lack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol. 2012; 39: 336-342.
102. Redmond WJ, Goffaux P, Potvin S, Marchand S,. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin. 2008; 24: 1017-1024.
103. Foltin RW, Brady JV, Fischman MW,. Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav. 1986; 25: 577-582.
104. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW,. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2002; 164: 407-415.
105. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A,. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005; 29: 358-367.
106. Haney M, Rabkin J, Gunderson E, Foltin RW,. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl). 2005; 181: 170-178.
107. Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr. 2007; 45: 545-554.
108. Riggs PK, Vaida F, Rossi SS, et al. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res. 2012; 1431: 46-52.
109. Timpone JG, Wright DJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses. 1997; 13: 305-315.
110. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995; 10: 89-97.
111. Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage. 1997; 14: 7-14.
112. Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011; 22: 2086-2093.
113. Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006; 24: 3394-3400.
114. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002; 20: 567-573.
115. Wade DT, Makela P, Robson P, House H, Bateman C,. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004; 10: 434-441.
116. Velasco G, Sanchez C, Guzman M,. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012; 12: 436-444.
117. Rocha FC, Dos Santos Junior JG, Stefano SC, da Silveira DX,. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol. 2014; 116: 11-24.
118. Pourkhalili N, Ghahremani MH, Farsandaj N, et al. Evaluation of anti-invasion effect of cannabinoids on human hepatocarcinoma cells. Toxicol Mech Methods. 2013; 23: 120-126.
119. De Petrocellis L, Ligresti A, Schiano Moriello A, et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 2013; 168: 79-102.
120. Ramer R, Bublitz K, Freimuth N, et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012; 26: 1535-1548.
121. Leelawat S, Leelawat K, Narong S, Matangkasombut O,. The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration. Cancer Invest. 2010; 28: 357-363.
122. Qamri Z, Preet A, Nasser MW, et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther. 2009; 8: 3117-3129.
123. Blazquez C, Carracedo A, Barrado L, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006; 20: 2633-2635.
124. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006; 95: 197-203.
125. Engels FK, de Jong FA, Sparreboom A, et al. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist. 2007; 12: 291-300.
126. Clinicaltrials.gov. A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma [ Clinicaltrials.gov identifier NCT01812603]. clinicaltrials.gov/show/NCT01812603. Accessed October 14, 2014.
127. Clinicaltrials.gov. A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients [ Clinicaltrials.gov identifier NCT01812616]. clinicaltrials.gov/show/NCT01812616. Accessed October 14, 2014.
128. Zhang ZF, Morgenstern H, Spitz MR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 1999; 8: 1071-1078.
129. Liang C, McClean MD, Marsit C, et al. A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cancer Prev Res (Phila). 2009; 2: 759-768.
130. Berthiller J, Lee YC, Boffetta P, et al. Marijuana smoking and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1544-1551.
131. Aldington S, Harwood M, Cox B, et al. Cannabis and Respiratory Disease Research Group. Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg. 2008; 138: 374-380.
132. Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1829-1834.
133. Berthiller J, Straif K, Boniol M, et al. Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol. 2008; 3: 1398-1403.
134. Callaghan RC, Allebeck P, Sidorchuk A,. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control. 2013; 24: 1811-1820.
135. Lacson JC, Carroll JD, Tuazon E, Castelao EJ, Bernstein L, Cortessis VK,. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer. 2012; 118: 5374-5383.
136. Daling JR, Doody DR, Sun X, et al. Association of marijuana use and the incidence of testicular germ cell tumors. Cancer. 2009; 115: 1215-1223.
137. Chacko JA, Heiner JG, Siu W, Macy M, Terris MK,. Association between marijuana use and transitional cell carcinoma. Urology. 2006; 67: 100-104.
138. Tashkin DP,. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013; 10: 239-247.
139. Theunissen EL, Kauert GF, Toennes SW, et al. Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. Psychopharmacology (Berl). 2012; 220: 341-350.
140. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR,. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol. 2009; 23: 266-277.
141. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW,. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology. 2001; 25: 757-765.
142. Atakan Z, Bhattacharyya S, Allen P, et al. Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychol Med. 2013; 43: 1255-1267.
143. D'Souza DC, Sewell RA, Ranganathan M,. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009; 259: 413-431.
144. Power RA, Verweij KJ, Zuhair M, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014; 19: 1201-1204.
145. Asbridge M, Hayden JA, Cartwright JL,. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2012; 344: e536.
146. Ramaekers JG, Theunissen EL, de Brouwer M, Toennes SW, Moeller MR, Kauert G,. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology (Berl). 2011; 214: 391-401.
147. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accid Anal Prev. 2010; 42: 1855-1865.
148. Sewell RA, Poling J, Sofuoglu M,. The effect of cannabis compared with alcohol on driving. Am J Addict. 2009; 18: 185-193.
149. Varner MW, Silver RM, Rowland Hogue CJ, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Stillbirth Collaborative Research Network. Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol. 2014; 123: 113-125.
150. Morris CV, DiNieri JA, Szutorisz H, Hurd YL,. Molecular mechanisms of maternal cannabis and cigarette use on human neurodevelopment. Eur J Neurosci. 2011; 34: 1574-1583.
151. Galli JA, Sawaya RA, Friedenberg FK,. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011; 4: 241-249.